novartis europharm limited
novartis europharm limited Company Information
Company Number
03068306
Next Accounts
Sep 2025
Shareholders
novartis pharma ag
Group Structure
View All
Industry
Other business support service activities n.e.c.
Registered Address
2nd floor, the westworks buildin, white city place, london, W12 7FQ
Website
www.glivec.comnovartis europharm limited Estimated Valuation
Pomanda estimates the enterprise value of NOVARTIS EUROPHARM LIMITED at £19.9k based on a Turnover of £36.6k and 0.54x industry multiple (adjusted for size and gross margin).
novartis europharm limited Estimated Valuation
Pomanda estimates the enterprise value of NOVARTIS EUROPHARM LIMITED at £6.9k based on an EBITDA of £1.7k and a 3.97x industry multiple (adjusted for size and gross margin).
novartis europharm limited Estimated Valuation
Pomanda estimates the enterprise value of NOVARTIS EUROPHARM LIMITED at £496.9k based on Net Assets of £232.9k and 2.13x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Novartis Europharm Limited Overview
Novartis Europharm Limited is a live company located in london, W12 7FQ with a Companies House number of 03068306. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in June 1995, it's largest shareholder is novartis pharma ag with a 100% stake. Novartis Europharm Limited is a mature, micro sized company, Pomanda has estimated its turnover at £36.6k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Novartis Europharm Limited Health Check
Pomanda's financial health check has awarded Novartis Europharm Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 4 areas for improvement. Company Health Check FAQs
1 Strong
2 Regular
4 Weak
Size
annual sales of £36.6k, make it smaller than the average company (£4.8m)
£36.6k - Novartis Europharm Limited
£4.8m - Industry AVG
Growth
3 year (CAGR) sales growth of -35%, show it is growing at a slower rate (6.7%)
-35% - Novartis Europharm Limited
6.7% - Industry AVG
Production
with a gross margin of 38.3%, this company has a comparable cost of product (38.3%)
38.3% - Novartis Europharm Limited
38.3% - Industry AVG
Profitability
an operating margin of 4.8% make it as profitable than the average company (5.7%)
4.8% - Novartis Europharm Limited
5.7% - Industry AVG
Employees
with 1 employees, this is below the industry average (27)
- Novartis Europharm Limited
27 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Novartis Europharm Limited
- - Industry AVG
Efficiency
resulting in sales per employee of £36.6k, this is less efficient (£171.3k)
- Novartis Europharm Limited
£171.3k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Novartis Europharm Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Novartis Europharm Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Novartis Europharm Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Novartis Europharm Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 10.9%, this is a lower level of debt than the average (62.5%)
10.9% - Novartis Europharm Limited
62.5% - Industry AVG
NOVARTIS EUROPHARM LIMITED financials
Novartis Europharm Limited's latest turnover from December 2023 is £36.6 thousand and the company has net assets of £232.9 thousand. According to their latest financial statements, we estimate that Novartis Europharm Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 36,584 | 1,761 | 66,527 | 130,860 | 373,520 | 7,091,754 | 8,243,949 | 7,535,519 | 6,153,282 | 6,987,805 | 6,912,230 | 6,069,420 | 5,207,740 | 3,974,638 | 5,712,297 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | 1,742 | 84 | 3,066 | 18,159 | 32,049 | 18,906 | 32,658 | 28,028 | 19,287 | 19,372 | 24,294 | 11,945 | 10,246 | 13,490 | 21,159 |
| Interest Payable | 13,583 | 10 | 1,180 | 1,653 | 16,453 | 11,989 | 5,013 | 8,072 | 9,776 | 7,638 | 6,073 | 1,946 | |||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | -11,841 | 74 | 1,886 | 16,506 | 15,596 | 6,917 | 27,645 | 19,956 | 9,511 | 11,734 | 18,221 | 9,999 | 10,246 | 13,490 | 21,159 |
| Tax | 2,818 | -14 | -491 | -2,853 | -3,183 | 4,735 | -5,770 | -4,350 | -3,087 | -4,458 | -5,573 | -4,389 | -4,736 | -5,635 | -8,462 |
| Profit After Tax | -9,023 | 60 | 1,395 | 13,653 | 12,413 | 11,652 | 21,875 | 15,606 | 6,424 | 7,276 | 12,648 | 5,610 | 5,510 | 7,855 | 12,697 |
| Dividends Paid | |||||||||||||||
| Retained Profit | -9,023 | 60 | 1,395 | 13,653 | 12,413 | 11,652 | 21,875 | 15,606 | 6,424 | 7,276 | 12,648 | 5,610 | 5,510 | 7,855 | 12,697 |
| Employee Costs | |||||||||||||||
| Number Of Employees | |||||||||||||||
| EBITDA* | 1,742 | 84 | 3,066 | 18,159 | 32,049 | 18,906 | 32,658 | 28,028 | 19,287 | 19,372 | 24,294 | 11,945 | 10,246 | 13,490 | 21,159 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | |||||||||||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | 133 | 155 | 212 | 281 | 449 | 571 | 719 | 1,005 | 1,407 | 1,879 | 2,538 | 3,290 | |||
| Total Fixed Assets | 133 | 155 | 212 | 281 | 449 | 571 | 719 | 1,005 | 1,407 | 1,879 | 2,538 | 3,290 | |||
| Stock & work in progress | |||||||||||||||
| Trade Debtors | |||||||||||||||
| Group Debtors | 258,705 | 620,476 | 669,884 | 670,065 | 1,097,788 | 2,534,393 | 3,156,402 | 3,497,967 | 2,993,263 | 3,282,227 | 3,943,821 | 4,017,259 | 3,665,281 | 3,784,117 | 6,053,018 |
| Misc Debtors | 91 | 2,495 | 4,097 | 107,368 | 98,896 | 346,513 | 974,064 | 16,450 | |||||||
| Cash | 111,183 | 59,447 | 62,956 | ||||||||||||
| misc current assets | 2,818 | ||||||||||||||
| total current assets | 261,523 | 620,476 | 669,975 | 670,065 | 1,100,283 | 2,538,490 | 3,263,770 | 3,596,863 | 3,339,776 | 4,256,291 | 3,943,821 | 4,017,259 | 3,776,464 | 3,843,564 | 6,132,424 |
| total assets | 261,523 | 620,476 | 669,975 | 670,198 | 1,100,438 | 2,538,702 | 3,264,051 | 3,597,312 | 3,340,347 | 4,257,010 | 3,944,826 | 4,018,666 | 3,778,343 | 3,846,102 | 6,135,714 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | |||||||||||||||
| Group/Directors Accounts | 28,580 | 361,825 | 416,168 | 416,711 | 811,652 | 2,297,087 | 2,721,189 | 3,016,567 | 2,109,961 | 2,827,437 | 1,733,530 | 2,081,896 | 3,629,171 | 3,702,725 | 5,993,877 |
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 16,685 | 11,901 | 12,976 | 61,928 | 27,170 | 340,069 | 399,827 | 1,065,074 | 1,270,685 | 2,059,684 | 1,797,806 | 15,818 | 15,533 | 21,848 | |
| total current liabilities | 28,580 | 378,510 | 428,069 | 429,687 | 873,580 | 2,324,257 | 3,061,258 | 3,416,394 | 3,175,035 | 4,098,122 | 3,793,214 | 3,879,702 | 3,644,989 | 3,718,258 | 6,015,725 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 28,580 | 378,510 | 428,069 | 429,687 | 873,580 | 2,324,257 | 3,061,258 | 3,416,394 | 3,175,035 | 4,098,122 | 3,793,214 | 3,879,702 | 3,644,989 | 3,718,258 | 6,015,725 |
| net assets | 232,943 | 241,966 | 241,906 | 240,511 | 226,858 | 214,445 | 202,793 | 180,918 | 165,312 | 158,888 | 151,612 | 138,964 | 133,354 | 127,844 | 119,989 |
| total shareholders funds | 232,943 | 241,966 | 241,906 | 240,511 | 226,858 | 214,445 | 202,793 | 180,918 | 165,312 | 158,888 | 151,612 | 138,964 | 133,354 | 127,844 | 119,989 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 1,742 | 84 | 3,066 | 18,159 | 32,049 | 18,906 | 32,658 | 28,028 | 19,287 | 19,372 | 24,294 | 11,945 | 10,246 | 13,490 | 21,159 |
| Depreciation | |||||||||||||||
| Amortisation | |||||||||||||||
| Tax | 2,818 | -14 | -491 | -2,853 | -3,183 | 4,735 | -5,770 | -4,350 | -3,087 | -4,458 | -5,573 | -4,389 | -4,736 | -5,635 | -8,462 |
| Stock | |||||||||||||||
| Debtors | -361,771 | -49,499 | -223 | -430,240 | -1,438,264 | -725,349 | -333,261 | 256,965 | -916,663 | 312,184 | -73,840 | 351,506 | -119,495 | -2,286,103 | 6,072,758 |
| Creditors | |||||||||||||||
| Accruals and Deferred Income | -16,685 | 4,784 | -1,075 | -48,952 | 34,758 | -312,899 | -59,758 | -665,247 | -205,611 | -788,999 | 261,878 | 1,781,988 | 285 | -6,315 | 21,848 |
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | 349,646 | 54,353 | 1,723 | 396,594 | 1,501,888 | 436,091 | 300,391 | -898,534 | 727,252 | -1,086,269 | 354,439 | 1,438,038 | 125,290 | 2,287,643 | -6,038,213 |
| Investing Activities | |||||||||||||||
| capital expenditure | -9,776 | ||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | -9,776 | ||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -333,245 | -54,343 | -543 | -394,941 | -1,485,435 | -424,102 | -295,378 | 906,606 | -717,476 | 1,093,907 | -348,366 | -1,547,275 | -73,554 | -2,291,152 | 5,993,877 |
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | -13,583 | -10 | -1,180 | -1,653 | -16,453 | -11,989 | -5,013 | -8,072 | -9,776 | -7,638 | -6,073 | -1,946 | |||
| cash flow from financing | -346,828 | -54,353 | -1,723 | -396,594 | -1,501,888 | -436,091 | -300,391 | 898,534 | -727,252 | 1,086,269 | -354,439 | -1,549,221 | -73,554 | -2,291,152 | 6,101,169 |
| cash and cash equivalents | |||||||||||||||
| cash | -111,183 | 51,736 | -3,509 | 62,956 | |||||||||||
| overdraft | |||||||||||||||
| change in cash | -111,183 | 51,736 | -3,509 | 62,956 |
novartis europharm limited Credit Report and Business Information
Novartis Europharm Limited Competitor Analysis
Perform a competitor analysis for novartis europharm limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other micro companies, companies in W12 area or any other competitors across 12 key performance metrics.
novartis europharm limited Ownership
NOVARTIS EUROPHARM LIMITED group structure
Novartis Europharm Limited has no subsidiary companies.
Ultimate parent company
NOVARTIS AG
#0001237
NOVARTIS PHARMA AG
#0033506
2 parents
NOVARTIS EUROPHARM LIMITED
03068306
novartis europharm limited directors
Novartis Europharm Limited currently has 3 directors. The longest serving directors include Mr Edward Fowler (Sep 2016) and Mr Jason Brooks (May 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Edward Fowler | United Kingdom | 48 years | Sep 2016 | - | Director |
| Mr Jason Brooks | United Kingdom | 52 years | May 2019 | - | Director |
| Mr Johan Kahlstroem | United Kingdom | 44 years | Nov 2024 | - | Director |
P&L
December 2023turnover
36.6k
+1977%
operating profit
1.7k
+1974%
gross margin
38.3%
-0.3%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
232.9k
-0.04%
total assets
261.5k
-0.58%
cash
0
0%
net assets
Total assets minus all liabilities
novartis europharm limited company details
company number
03068306
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
June 1995
age
30
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
ciba europharm limited (March 1997)
accountant
-
auditor
KPMG LLP
address
2nd floor, the westworks buildin, white city place, london, W12 7FQ
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
novartis europharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to novartis europharm limited.
novartis europharm limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NOVARTIS EUROPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.
novartis europharm limited Companies House Filings - See Documents
| date | description | view/download |
|---|
